Infliximab for kidney injury caused by immunotherapy
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether infliximab can treat kidney damage caused by immune checkpoint inhibitor cancer therapy. It aims to see if this medication helps patients recover kidney function after injury from their cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have had acute kidney injury (sudden kidney function decline) with at least 50% rise in serum creatinine compared to before starting your cancer immunotherapy
- You must have received an immune checkpoint inhibitor (a type of cancer drug that boosts the immune system) within the 6 months before your kidney injury
- The kidney injury must be caused by inflammation from the immune system therapy, confirmed by a kidney biopsy or your doctor's clinical judgment
- You must not be on certain other immune-suppressing drugs or high-dose steroids within 14 days of starting the study
- You must have no active infections (like tuberculosis, hepatitis B/C, or HIV) or uncontrolled conditions, and no history of multiple sclerosis, heart failure, or allergies to infliximab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called cilastatin can prevent kidney damage caused by certain strong medications. If you are receiving one of these medications and are at risk for kidney injury, this trial may offer protection.
This study tests whether a drug called infliximab can help preserve insulin-making cells in people who develop diabetes after receiving immune checkpoint inhibitor (ICI) cancer treatment. It aims to improve blood sugar control and reduce the need for insulin.
This study looks at how immune checkpoint medicines (sometimes combined with other treatments like chemotherapy) may affect the kidneys. It may help doctors better prevent or manage kidney side effects in people starting these therapies.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This trial tests a new cell therapy called GT719 that targets B cells, part of the immune system that attacks the kidneys in several types of autoimmune kidney disease. It is designed for people whose kidney disease has not improved with standard treatments.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.